Clinical Relevance of Urokinase-Type Plasminogen Activator, Its Receptor, and Its Inhibitor Type 1 in Endometrial Cancer
Authors:
- Coşkun TecimerCTCoşkun Tecimer
- David L. DoeringDDDavid L. Doering
- L.Jane GoldsmithLGL.Jane Goldsmith
- John S. MeyerJMJohn S. Meyer
- Gazi AbdulhayGAGazi Abdulhay
- James L. WittliffJWJames L. Wittliff
- 1 January 2001
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 80 (1) , 48-55
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- The urokinase-type plasminogen activator system in cancer metastasis: A reviewInternational Journal of Cancer, 1997
- Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinomaCancer, 1996
- Urokinase (uPA) and PAI-1 Predict Survival in Advanced Ovarian Cancer Patients (FIGO III) after Radical Surgery and Platinum-Based ChemotherapyGynecologic Oncology, 1994
- Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancerThe Lancet, 1994
- Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancerThe Lancet, 1994
- Biology and biochemistry of proteinases in tumor invasionPhysiological Reviews, 1993
- The content of urokinase‐type plasminogen activator antigen as a prognostic factor in urinary bladder cancerInternational Journal of Cancer, 1992
- Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary reportCancer, 1988
- The Role of Hemostasis and Fibrinolysis in the Metastatic Spread of CancerSeminars in Thrombosis and Hemostasis, 1984